Data Sheet (Cat.No.TMPK-00708)

TargetMol

TRAIL R1/DR4/TNFRSF10A Protein, Human, Recombinant (hFc)

General Information

Synonyms:	TRAIL R1;APO2;DR4;CD261;TRAIL-R;TNFRSF10A;MGC9365
Protein Construction:	Pro34-Asn239
Species:	Human
Expression Host:	HEK293 Cells
Accession:	O00220
Molecular Weight:	48.8 kDa (predicted). Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Human TRAIL, No Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 51.6ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.

Reference

Deng D, Shah K. TRAIL of Hope Meeting Resistance in Cancer. Trends Cancer. 2020 Dec;6(12):989-100 doi: 10.1016/j.trecan.2020.06.006. Epub 2020 Jul 24. PMID: 32718904; PMCID: PMC7688478.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481